LSP’s portfolio company eTheRNA launches SARS-CoV-2 mRNA vaccine program for COVID-19



eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective                                         CoV-2 mRNA Vaccine for High Risk Populations

 

Amsterdam, The Netherlands, March 25, 2020 – LSP’s portfolio company eTheRNA ('eTheRNA' or 'The Company'), a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium has been formed with North American and European partners to develop a novel mRNA vaccine against CoV-2 and preclinical development has started. Chinese partners may be added in the consortium in due course.

 

Administered intranasally, the proposed vaccine is intended primarily for high risk populations such as healthcare workers and families of confirmed cases. It is also designed to be protective against future variations of the virus by targeting conserved epitopes from the whole CoV-2 genome. eTheRNA and its partners EpiVax, Nexelis, REPROCELL and CEV have extensive experience in the mRNA vaccine field and this will help accelerate progress towards clinical trials with patient enrolment expected in early 2021.

 

Steven Powell, eTheRNA's CEO, explained the aims of the consortium: "Viral variation means traditional medicinal and preventive vaccine approaches may fall short when confronted with seasonal or outbreak situations. A vaccine to defend against current and future outbreaks of coronavirus and other respiratory viral pathogens should be robust against viral genome changes, provide a platform that enables rapid introduction of a new viral target, be easy and safe to administer and be scaleable and suitable for stockpiling. The innovative vaccine program we have started with our partners incorporates all of these essential features.”

 

Traditional vaccines are based on generating an antibody response to outer surface viral protein targets. However, viral variation may greatly reduce the effectiveness of this approach. For example, the SARS-CoV-2 outer surface spike protein (S) is less than 40% homologous to SARS-CoV-1. Furthermore, it has also been reported in several cases that vaccines with suboptimal antibody response (too low or not neutralizing) have facilitated viral entry and been linked to disease enhancement.

 

The eTheRNA consortium's approach selects conserved epitopes from the whole viral genome. Creating a vaccine that mounts a strong cellular (T cell) based response against these epitopes offers a better chance to overcome viral variability. Intranasal delivery has been chosen since the mucosa of the upper respiratory tract are the immune system's primary line of defense. A strong nasal T cell effector and memory response is claimed to fight viral replication, colonization of the lung and thus disease. mRNA has also been demonstrated to induce strong T cell responses by intranasal delivery.

 

The development programme has been initiated and is focused on a vaccine candidate that integrates 3 different technologies:

  • eTheRNA's proprietary Trimix technology: an mRNA-based vaccine adjuvant that stimulates dendritic cells into activating a strong CD4 and CD8 T cell response.
  • A combination of T cell epitopes from the virus brought together on a single mRNA construct. For SARS-CoV-2 this will employ an in-silico epitope prediction and design approach from EpiVax Inc. to identify the target.
  • An intranasal vaccine delivery platform using a nasal atomizer and a proprietary formulation that delivers the mRNA to the nasal mucosa and optimizes expression. One of the most promising formulation candidates is being repurposed for clinical use in collaboration with REPROCELL.

 

"While valuable initiatives and strong support are being deployed into the development of medicinal and vaccine solutions for immediate use against SARS-CoV-2, it is also important that development of solutions for the longer term should also start as soon as possible," concluded Powell. "Our target is to bring this into clinical testing in early 2021."

 

About eTheRNA

eTheRNA immunotherapies is a clinical-stage company developing innovative immunotherapies from its proprietary mRNA TriMix platform. eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium and is developing products for the treatment of cancer and infectious disease.

 

 
About TriMix
The TriMix platform, on which eTheRNA's immunotherapies are based, comprises three mRNAs encoding proteins (caTLR4, CD40L and CD70) that work to deliver optimal activation of dendritic cells. These cells behave as immune response mediators and mobilize the immune system to attack cancer cells through inducing a T-cell response. Clinical proof of concept for TriMix-based immunotherapies has been established through an extensive dataset demonstrating clinical benefits in advanced melanoma patients.
 
 
About LSP
LSP (Life Sciences Partners) is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s, LSP’s management has invested in over 120 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With $2.5 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s leading life sciences investors. For more information, please visit
 
 
Contact:
Dr John de Koning
Te: +31 (0)20 664 5500
 

 

« back to overview

go to archive back to news overview
Follow us

LSP’s portfolio company eTheRNA launches SARS-CoV-2 mRNA vaccine program for COVID-19



eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective                                         CoV-2 mRNA Vaccine for High Risk Populations

 

Amsterdam, The Netherlands, March 25, 2020 – LSP’s portfolio company eTheRNA ('eTheRNA' or 'The Company'), a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium has been formed with North American and European partners to develop a novel mRNA vaccine against CoV-2 and preclinical development has started. Chinese partners may be added in the consortium in due course.

 

Administered intranasally, the proposed vaccine is intended primarily for high risk populations such as healthcare workers and families of confirmed cases. It is also designed to be protective against future variations of the virus by targeting conserved epitopes from the whole CoV-2 genome. eTheRNA and its partners EpiVax, Nexelis, REPROCELL and CEV have extensive experience in the mRNA vaccine field and this will help accelerate progress towards clinical trials with patient enrolment expected in early 2021.

 

Steven Powell, eTheRNA's CEO, explained the aims of the consortium: "Viral variation means traditional medicinal and preventive vaccine approaches may fall short when confronted with seasonal or outbreak situations. A vaccine to defend against current and future outbreaks of coronavirus and other respiratory viral pathogens should be robust against viral genome changes, provide a platform that enables rapid introduction of a new viral target, be easy and safe to administer and be scaleable and suitable for stockpiling. The innovative vaccine program we have started with our partners incorporates all of these essential features.”

 

Traditional vaccines are based on generating an antibody response to outer surface viral protein targets. However, viral variation may greatly reduce the effectiveness of this approach. For example, the SARS-CoV-2 outer surface spike protein (S) is less than 40% homologous to SARS-CoV-1. Furthermore, it has also been reported in several cases that vaccines with suboptimal antibody response (too low or not neutralizing) have facilitated viral entry and been linked to disease enhancement.

 

The eTheRNA consortium's approach selects conserved epitopes from the whole viral genome. Creating a vaccine that mounts a strong cellular (T cell) based response against these epitopes offers a better chance to overcome viral variability. Intranasal delivery has been chosen since the mucosa of the upper respiratory tract are the immune system's primary line of defense. A strong nasal T cell effector and memory response is claimed to fight viral replication, colonization of the lung and thus disease. mRNA has also been demonstrated to induce strong T cell responses by intranasal delivery.

 

The development programme has been initiated and is focused on a vaccine candidate that integrates 3 different technologies:

  • eTheRNA's proprietary Trimix technology: an mRNA-based vaccine adjuvant that stimulates dendritic cells into activating a strong CD4 and CD8 T cell response.
  • A combination of T cell epitopes from the virus brought together on a single mRNA construct. For SARS-CoV-2 this will employ an in-silico epitope prediction and design approach from EpiVax Inc. to identify the target.
  • An intranasal vaccine delivery platform using a nasal atomizer and a proprietary formulation that delivers the mRNA to the nasal mucosa and optimizes expression. One of the most promising formulation candidates is being repurposed for clinical use in collaboration with REPROCELL.

 

"While valuable initiatives and strong support are being deployed into the development of medicinal and vaccine solutions for immediate use against SARS-CoV-2, it is also important that development of solutions for the longer term should also start as soon as possible," concluded Powell. "Our target is to bring this into clinical testing in early 2021."

 

About eTheRNA

eTheRNA immunotherapies is a clinical-stage company developing innovative immunotherapies from its proprietary mRNA TriMix platform. eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium and is developing products for the treatment of cancer and infectious disease.

 

 
About TriMix
The TriMix platform, on which eTheRNA's immunotherapies are based, comprises three mRNAs encoding proteins (caTLR4, CD40L and CD70) that work to deliver optimal activation of dendritic cells. These cells behave as immune response mediators and mobilize the immune system to attack cancer cells through inducing a T-cell response. Clinical proof of concept for TriMix-based immunotherapies has been established through an extensive dataset demonstrating clinical benefits in advanced melanoma patients.
 
 
About LSP
LSP (Life Sciences Partners) is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s, LSP’s management has invested in over 120 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With $2.5 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s leading life sciences investors. For more information, please visit
 
 
Contact:
Dr John de Koning
Te: +31 (0)20 664 5500
 

 

« back to overview

go to archive back to newsoverview